Table 1.
Demographic and clinical (during baseline evaluation) characteristics of enrolled subjects. The daily levodopa equivalent dosage (LED) at the start and end of the study are also provided. Subject 14 did not complete the study for reasons unrelated to the study.
| S. No. | Age (years) |
Weight (kg) |
Height (cm) |
Gender | H&Y score |
UPDRS-I | UPDRS-II | UPDRS-III | LED (mg/d) Start |
LED (mg/d) End |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 67 | 65.5 | 155 | F | 3 | 1 | 10 | 18 | 300 | 300 |
|
| ||||||||||
| 2 | 64 | 79.5 | 175 | M | 2.5 | 0 | 6 | 18 | 489 | 637 |
|
| ||||||||||
| 3 | 66 | 77.3 | 170 | M | 2.5 | 0 | 7 | 5 | 240 | 740 |
|
| ||||||||||
| 4 | 68 | 90.1 | 180 | M | 3 | 0 | 3 | 21 | 420 | 520 |
|
| ||||||||||
| 5 | 53 | 72.7 | 178 | M | 3 | 1 | 14 | 17 | 676 | 536 |
|
| ||||||||||
| 6 | 66 | 100 | 165 | F | 2.5 | 1 | 9 | 13 | 1000 | 900 |
|
| ||||||||||
| 7 | 66 | 94.5 | 171 | F | 3 | 3 | 9 | 17 | 600 | 800 |
|
| ||||||||||
| 8 | 63 | 88.6 | 175 | M | 3 | 2 | 9 | 23 | 400 | 400 |
|
| ||||||||||
| 9 | 72 | 68.5 | 163 | F | 2.5 | 2 | 8 | 16 | 250 | 250 |
|
| ||||||||||
| 10 | 60 | 66.4 | 173 | F | 2.5 | 0 | 4 | 12 | 375 | 375 |
|
| ||||||||||
| 11 | 60 | 59.73 | 155 | F | 2.5 | 1 | 2 | 9 | 325 | 325 |
|
| ||||||||||
| 12 | 69 | 95 | 175 | M | 3 | 0 | 8 | 19 | 525 | 650 |
|
| ||||||||||
| 13 | 69 | 88.1 | 173 | F | 2.5 | 0 | 2 | 8 | 400 | 400 |
|
| ||||||||||
| 14 | 60 | 107 | 165 | F | 3 | 1 | 5 | 21 | 400 | 199 |
|
| ||||||||||
| 15 | 58 | 86.4 | 170 | M | 3 | 0 | 4 | 9 | 750 | 750 |
|
| ||||||||||
| 16 | 64 | 62.3 | 160 | F | 3 | 2 | 7 | 11 | 75 | 200 |
|
| ||||||||||
| 17 | 58 | 130.1 | 178 | M | 3 | 1 | 12 | 39 | 158 | 132 |